佐匹克隆联合参芪五味子胶囊治疗失眠的疗效观察  

Effect observation of Zopiclone tablets combined with Shenqi Wuweizi capsules in treatment of insomnia

作　　者：高莹[1] 杨晓松[1] 鲁晶[1] 刘晓雯[1] 

机构地区：[1]解放军第210医院药剂科,辽宁大连110021

出　　处：《临床军医杂志》2014年第6期576-578,共3页Clinical Journal of Medical Officers

摘　　要：目的观察佐匹克隆联合参芪五味子胶囊治疗失眠症的临床疗效与不良反应。方法将符合诊断标准的140例失眠患者按就诊顺序分为治疗组和对照组,每组70例。对照组给予口服佐匹克隆片;治疗组在对照组基础上加用参芪五味子胶囊;两组疗程均为4周,治疗前和治疗后2、4周末采用匹兹堡睡眠质量指数量表(PSQI)评价疗效,治疗药物副反应量表(TESS)评定药物不良反应。结果两组均有明显疗效,治疗组总有效率为88.6%,对照组总有效率为71.4%,两组疗效比较差异有统计学意义(P<0.05);治疗后两组的PSQI评分均显著降低(P<0.01),4周末治疗组的PSQI评分显著低于对照组(P<0.05);治疗组不良反应发生率显著低于对照组(P<0.01)。结论佐匹克隆联合参芪五味子胶囊治疗失眠症疗效确切。Objective To explore the clinical effect of Zopiclone tablets combined with Shenqi Wuweizi capsules on insomnia and their adverse reaction. Methods A total of 140 patients with insomnia were divided into trial group and control group by the sick call sequence （n = 70/group）. The control group was treated with oral Zopiclone tablets alone, and the trial group was treated with Zopielone tablets and Shenqi Wuweizi capsules. Therapies lasted for 4 weeks for both groups. Pittsburgh sleep quality index （PSQI） was adopted to evaluate the sleep changes of the patients before treatment and after 2 and 4 weeks＇ treatment. Treatment emergent symptom scale （TESS） was adopted to evaluate adverse drug reactions. Results The total effective rate of the trial group was 88.6% , and that of the control group was 71.4%. The difference was of statistical significance between two groups （P 〈 0. 05 ）. The PSQI scores of the two groups were significantly decreased after the treatment （P 〈 0. 01 ）. The PSQI score of the trial group was significantly lower than that of the control group after 4 weeks＇ treatment （ P 〈 0.05 ）. TESS was significantly lower in the trial group than in the control group （ P 〈 0.01 ）. Conclusion Zopiclone tablets combined with Shenqi Wuweizi capsules is of good treatment effect on insomnia.

关 键 词：佐匹克隆片 参芪五味子胶囊 失眠症 

分 类 号：R749.7[医药卫生—神经病学与精神病学]